Loading
HB1801 is an experimental investigational agent whose form is not stated in the registry from Shanghai JMT-Bio in phase 3 trials for HER2-positive breast cancer, with its target not yet stated publicly.
HB1801 is an investigational agent whose form is not stated in the registry developed by Shanghai JMT-Bio. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT05838066 (Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer), NCT07441460 (A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer) and NCT06747338 (A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer), in HER2-positive breast cancer. The largest, NCT07441460, plans to enrol 1800 participants with primary completion expected 2034-08-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.HB1801 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HB1801" OR ABSTRACT:"HB1801") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HB1801, not a curated reading list.
Shares A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer, A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer, CSPC Pharmaceutical Group, HER2-positive breast cancer and the tag pipeline.
Shares Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer, CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.